Independent Director Nominees Brian Coffman, Sigmund Cornelius, Michael Heim and Stacy Nieuwoudt Outline How Their Skills and Experiences Will Drive Positive Change at the Company Intend to Work Constructively with Incumbent Directors to Create Value for All Shareholders Elliott Urges Shareholders to Support Meaningful Board Change By Voting on the Gold Card for Its Four […]
Transaction Follows Successful Transformation of Leading Insurance Data and Analytics Provider GTCR, a leading private equity firm, announced that it has signed a definitive agreement to sell ITEL Laboratories, Inc. (“itel” or “the Company”), a leading provider of data and analytics to the P&C insurance industry, to Nearmap, a portfolio company of Thoma Bravo. https://mma.prnewswire.com/media/2624007/GTCR_Logo.jpg
While navigating economic headwinds and financial concerns, summer travelers adjust budgets and itineraries but maintain their plans https://mma.prnewswire.com/media/2691273/Deloitte___2025_Summer_Travel_Survey1.jpg Key takeaways — Financial pressures may be top-of-mind, but Americans are determined to take their summer trips, as 53% of those surveyed in April plan to travel and stay in paid lodging, up from 48% last year.
Ashford Securities LLC (“Ashford Securities”), a wholly owned subsidiary of Ashford Inc. (“Ashford”), is pleased to announce the addition of two accomplished professionals to its team. Jonathan Dease has joined as Senior Vice President, National Accounts, and Melissa Birdsall has been named Regional Vice President of Sales (Central Region). These individuals will play important roles
Agreement broadly reached on PT-112 Recommended Phase 3 Dose (RP3D), patient population, study comparator and key study endpoints Interim analysis allows potential for drug approval prior to study completion Preliminary PT-112 Phase 2 clinical outcomes in metastatic castration-resistant prostate cancer patients will be presented at the ASCO 2025 Annual Meeting Promontory Therapeutics Inc., a clinical
Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are in talks with an international healthcare innovation company to license or potentially acquire its patented early disease detection
The first step in a broader vision to build AI where your knowledge already lives. Spike, the pioneer in transforming email into a modern workspace, unveils its latest innovation: the Spike AI Feed. This real-time feature uses AI to instantly summarize your inbox, offering clarity at a glance without opening a single message. Unlike extensions
Two new studies demonstrate the use of adeno-associated viral vectors for brain gene therapies Adeno-associated viral (AAV) vectors are promising tools that can transport modified genetic material into the nuclei of cells in target tissues impacted by challenging diseases, offering the possibility of a one-time precision therapy to inherited diseases. Now, with two recently published
ATG-022 isAntengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced it has entered into a global clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA)
ATG-022 isAntengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced it has entered into a global clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA)